Big pharma is dabbling in systems biology, a few brave entrepreneurs are trying to make a business out of it, but investor caution may keep those in the field from really making it big in drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Skomorovski, K. et al. New TPO treatment schedules of increased safety and efficacy: pre-clinical validation of a thrombopoiesis simulation model. British J. Haematol. 123, 683–691 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mack, G. Can complexity be commercialized?. Nat Biotechnol 22, 1223–1229 (2004). https://doi.org/10.1038/nbt1004-1223
Issue Date:
DOI: https://doi.org/10.1038/nbt1004-1223